Sonoma Pharmaceuticals, Inc. reported a total revenue of $19.5 million for the fiscal year ending March 31, 2026, marking a 37% increase from $14.3 million in the previous year. The growth was driven by a significant 117% increase in U.S. sales, primarily attributed to higher demand for over-the-counter products and expanded distribution channels. Revenue from Europe and Asia also saw increases of 25%, while Latin America experienced a 20% decline, largely due to timing issues with customer orders.
The company's gross profit for the year was $7.4 million, maintaining a consistent gross profit margin of 38%. Research and development expenses rose by 25% to $2.3 million, reflecting increased investment in product development to support new releases. Selling, general, and administrative expenses increased slightly by 3% to $7.6 million, primarily due to inflation-driven salary increases in Mexico. Sonoma reported a net loss of $3.2 million, a slight improvement from the $3.5 million loss in the prior year.
Strategically, Sonoma has made significant advancements, including the U.S. retail launch of its HOCl-based burn relief hydrogel in major retailers like CVS and Walmart. The company also introduced new products, such as the Aquanil® AD dermatology line and expanded its distribution agreements, including a notable partnership with Medline Industries for wound care products. These initiatives are part of Sonoma's broader strategy to enhance its product offerings and market presence.
Operationally, Sonoma's workforce consisted of 9 full-time employees in the U.S. and 250 in Mexico as of June 12, 2026. The company continues to focus on expanding its international reach, with products sold in over 55 countries. The filing indicates that Sonoma is committed to investing in research and development to further its core hypochlorous acid technology and is actively seeking new regulatory approvals to broaden its market opportunities.
Looking ahead, Sonoma Pharmaceuticals anticipates that its existing cash reserves, along with proceeds from recent capital raises, will be sufficient to fund operations for at least the next twelve months. However, the company acknowledges potential risks, including reliance on key customers for revenue and exposure to foreign currency fluctuations, which could impact financial performance. The management remains optimistic about future growth driven by ongoing product development and market expansion efforts.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals specializes in developing and manufacturing stabilized hypochlorous acid (HOCl) products for healthcare and disinfection. Its core segments include wound care, dermatology, eye, oral, nasal, podiatry, animal health, and surface disinfectants. The company markets globally through direct sales and partnerships, emphasizing safe, effective, and cost-efficient solutions backed by extensive regulatory approvals and proprietary technology.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.